Midha KK, Rawson MJ, Hubbard JW. The bioequivalence of highly variable drugs and drug products. Int J Clin Pharmacol Ther. 2005;43(10):485–98.
Ruiz-Picazo A, Colon-Useche S, Perez-Amoros B, et al. Investigation to explain bioequivalence failure in Pravastatin Immediate-Release Products. Pharmaceutics. 2019;11(12). https://doi.org/10.3390/pharmaceutics11120663.
Davies M, Jones RDO, Grime K, et al. Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons learned from the AstraZeneca Drug Pipeline over two decades. Trends Pharmacol Sci. 2020;41(6):390–408.
Zhuang X, Lu C. PBPK modeling and simulation in drug research and development. Acta Pharm Sin B. 2016;6(5):430–40.
Lin W, Chen Y, Unadkat JD, Zhang X, Wu D, Heimbach T. Applications, Challenges, and Outlook for PBPK modeling and Simulation: A Regulatory, Industrial and Academic Perspective. Pharm Res. 2022;39(8):1701–731.
Zhu J, Zhao Y, Wang L, et al. Physiologically based pharmacokinetic/pharmacodynamic modeling to evaluate the absorption of midazolam rectal gel. Eur J Pharm Sci. 2021;167:106006. https://doi.org/10.1016/j.ejps.2021.106006.
Wang K, Jiang K, Wei X, Li Y, Wang T, Song Y. Physiologically based pharmacokinetic models are effective support for Pediatric Drug Development. AAPS PharmSciTech. 2021;22(6):208.
Dong Z, Li J, Wu F, et al. Application of physiologically-based pharmacokinetic modeling to Predict gastric pH-Dependent drug-drug interactions for weak base drugs. CPT Pharmacometrics Syst Pharmacol. 2020;9(8):456–65.
Kesharwani SS, Ibrahim F. A combined In-Vitro and GastroPlus(R) modeling to Study the Effect of Intestinal Precipitation on Cinnarizine plasma Profile in a fasted state. AAPS PharmSciTech. 2023;24(5):121.
Bhattiprolu AK, Kollipara S, Ahmed T, Boddu R, Chachad S. Utility of physiologically based biopharmaceutics modeling (PBBM) in Regulatory Perspective: application to Supersede f2, enabling Biowaivers & Creation of Dissolution Safe Space. J Pharm Sci. 2022;111(12):3397–410.
Basu S, Yang H, Fang L, et al. Physiologically based pharmacokinetic modeling to evaluate formulation factors influencing bioequivalence of Metoprolol Extended-Release Products. J Clin Pharmacol. 2019;59(9):1252–263.
Zhang S, Fang M, Zhang Q, Li X, Zhang T. Evaluating the bioequivalence of metronidazole tablets and analyzing the effect of in vitro dissolution on in vivo absorption based on PBPK modeling. Drug Dev Ind Pharm. 2019;45(10):1646–653.
Duque MD, Silva DA, Issa MG, Porta V, Lobenberg R, Ferraz HG. In Silico Prediction of plasma concentrations of Fluconazole Capsules with different dissolution profiles and Bioequivalence Study using Population Simulation. Pharmaceutics. 2019;11(5). https://doi.org/10.3390/pharmaceutics11050215.
Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 2003;42(13):1141–60.
Liu YM, Pu HH, Liu GY, et al. Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted chinese adult males. Clin Ther Jul. 2010;32(7):1396–407.
Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther. 2005;78(2):154–67.
Gibson DM, Bron NJ, Richens A, Hounslow NJ, Sedman AJ, Whitfield LR. Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol. 1996;36(3):242–6.
Xu SM, Yan J, Li D, Li D, Li XM, Xu PS. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products of atorvastatin in chinese subjects. Int J Clin Pharmacol Ther. 2020;58(2):112–20.
Mohammad S, Arshad U, Abbass N, Parvez I, Abbas G, Mahmood W. Bioequivalence study of atorvastatin tablets in healthy pakistani volunteers. Therapie. 2015;70(4):329–35.
Zhang T. Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites. Eur J Pharm Sci. 2015;77:216–29.
Li S, Yu Y, Jin Z, et al. Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling. Biomed Pharmacother. 2019;119:109416.
Duan P, Zhao P, Zhang L. Physiologically based pharmacokinetic (PBPK) modeling of Pitavastatin and Atorvastatin to predict drug-drug interactions (DDIs). Eur J Drug Metab Pharmacokinet. 2017;42(4):689–705.
Li J, Volpe DA, Wang Y, et al. Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos. 2011;39(7):1196–202.
Mitra A, Petek B, Bajc A, Velagapudi R, Legen I. Physiologically based absorption modeling to predict bioequivalence of controlled release and immediate release oral products. Eur J Pharm Biopharm. 2019;134:117–25.
Ni Z, Talattof A, Fan J, et al. Physiologically based pharmacokinetic and absorption modeling for osmotic pump products. AAPS J. 2017;19(4):1045–053.
Heimbach T, Suarez-Sharp S, Kakhi M, et al. Dissolution and translational modeling strategies toward establishing an in Vitro-In vivo Link-a workshop Summary Report. AAPS J. 2019;21(2):29.
Suarez-Sharp S, Cohen M, Kesisoglou F, et al. Applications of clinically relevant Dissolution Testing: Workshop Summary Report. AAPS J. 2018;20(6):93.
Grimm M, Koziolek M, Kuhn JP, Weitschies W. Interindividual and intraindividual variability of fasted state gastric fluid volume and gastric emptying of water. Eur J Pharm Biopharm. 2018;127:309–17.
Fang L, Kim MJ, Li Z, et al. Model-informed Drug Development and Review for Generic Products: Summary of FDA Public Workshop. Clin Pharmacol Ther. 2018;104(1):27–30.
Add Comment